Objectives: We report the effectiveness and safety of certolizumab pegol (CZP) treatment in a real-world Greek axial spondyloarthritis (axSpA) population, including patients with radiographic (r-axSpA) and non-radiographic (nr-axSpA) disease.
Methods: We performed a sub-analysis of the Greek cohort from CIMAX (NCT02354105), a multicentre, non-interventional cohort study that prospectively investigated CZP treatment in patients with axSpA. The primary outcome was change from baseline (CfB) in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) to Week 52.
Results: Across 12 sites in Greece, 126 patients (r-axSpA: 91; nr-axSpA: 35) received ≥1 dose of CZP and were included in the Safety Set (SS), with 120 patients (r-axSpA: 86; nr-axSpA: 34) included in the Full Analysis Set (FAS). The mean (standard deviation [SD]) CfB in BASDAI at Week 52 was -3.8 (2.0) in the overall axSpA population, with numerically greater improvements observed for nr-axSpA patients compared with r-axSpA (nr-axSpA: -4.2 [2.1]; r-axSpA: -3.7 [2.0]). Improvements in the axSpA population, including r-axSpA and nr-axSpA subpopulations, were observed in key secondary and additional outcomes at Week 52. Overall, 14.3% (18/126) of patients in the axSpA population experienced ≥1 adverse event (AE). There were no serious AEs or deaths reported during the study.
Conclusions: Patients with r-axSpA and nr-axSpA treated with CZP in clinical practice in Greece showed improvements in disease activity and key symptoms. CZP treatment may therefore help address the substantial health burden associated with axSpA in Greece.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450185 | PMC |
| http://dx.doi.org/10.31138/mjr.33.1.162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of Extra-Musculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis.
Arthritis Rheumatol
December 2024
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Article Synopsis
- The study aimed to evaluate the occurrence of extra-musculoskeletal manifestations (EMMs) in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with a specific medication, upadacitinib (UPA15).
- Data from five clinical trials were analyzed to compare adverse events like uveitis and inflammatory bowel disease (IBD) among patients receiving either UPA15, a placebo, or adalimumab (ADA).
- Results showed that most patients did not have a history of EMMs, and the occurrence of uveitis and IBD was generally low, particularly in those treated with UPA15 compared to the placebo.
Deciphering miRNA signatures in axial spondyloarthritis: The link between miRNA-1-3p and pro-inflammatory cytokines.
Heliyon
October 2024
Institute of Rheumatology, Na Slupi 450/4, 128 00, Prague, Czech Republic.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that affects the spine and sacroiliac joints. Early detection of axSpA is crucial to slow disease progression and maintain remission or low disease activity. However, current biomarkers are insufficient for diagnosing axSpA or distinguishing between its radiographic (r-axSpA) and non-radiographic (nr-axSpA) subsets.
View Article and Find Full Text PDFPerformance analysis of a deep-learning algorithm to detect the presence of inflammation in MRI of sacroiliac joints in patients with axial spondyloarthritis.
Ann Rheum Dis
October 2024
Rheumatology Department, Cochin Hospital, Paris, France.
Objectives: To assess the ability of a previously trained deep-learning algorithm to identify the presence of inflammation on MRI of sacroiliac joints (SIJ) in a large external validation set of patients with axial spondyloarthritis (axSpA).
Methods: Baseline SIJ MRI scans were collected from two prospective randomised controlled trials in patients with non-radiographic (nr-) and radiographic (r-) axSpA (RAPID-axSpA: NCT01087762 and C-OPTIMISE: NCT02505542) and were centrally evaluated by two expert readers (and adjudicator in case of disagreement) for the presence of inflammation by the 2009 Assessment of SpondyloArthritis International Society (ASAS) definition. Scans were processed by the deep-learning algorithm, blinded to clinical information and central expert readings.
Prevalence of Axial Spondyloarthritis in Young People With Chronic Low Back Pain at a Hospital-Based Health Management Organization: A 10-Year Database Study.
J Clin Rheumatol
September 2024
From the Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires.
Article Synopsis
- This study investigates the prevalence of axial spondylarthritis (axSpA) in young people with chronic low back pain (LBP) using the ASAS 2009 criteria, focusing on data from a university hospital in Buenos Aires, Argentina.
- Among 795 patients reviewed, the estimated prevalence of axSpA was about 5.78%, with a notable proportion (21.74%) of cases being undiagnosed.
- The findings suggest that the high rate of undiagnosed axSpA could contribute to the lower prevalence rates previously reported in Latin America.
Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis.
RMD Open
August 2024
Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium.
Article Synopsis
- This study looked at how well a drug called certolizumab pegol (CZP) works for people with a condition called axial spondyloarthritis (axSpA) over 12 weeks.
- It found that while most patients showed strong improvements in inflammation measured by tests like blood tests and MRI scans, fewer than half showed similar improvements in their symptoms or daily activities.
- The results suggest that looking at inflammation alone might not give the full picture of how the treatment is working for patients with axSpA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!